DK2170877T3 - Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering - Google Patents

Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering

Info

Publication number
DK2170877T3
DK2170877T3 DK08773372.1T DK08773372T DK2170877T3 DK 2170877 T3 DK2170877 T3 DK 2170877T3 DK 08773372 T DK08773372 T DK 08773372T DK 2170877 T3 DK2170877 T3 DK 2170877T3
Authority
DK
Denmark
Prior art keywords
oxazolidinon
coagulation
substituted
methyl
field
Prior art date
Application number
DK08773372.1T
Other languages
English (en)
Other versions
DK2170877T5 (da
Inventor
Joachim Krueger
Susanne Roehrig
Holger Paulsen
Swen Allerheiligen
Stefan Heitmeier
Mark Jean Gnoth
Ulrich Rester
Elke Dittrich-Wengenroth
Uwe Saatmann
Adrian Tersteegen
Marcus Bauser
Dirk Heimbach
Christoph Gerdes
Degenfeld Georges Von
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2170877(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Application granted granted Critical
Publication of DK2170877T3 publication Critical patent/DK2170877T3/da
Publication of DK2170877T5 publication Critical patent/DK2170877T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK08773372.1T 2007-06-20 2008-06-07 Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering DK2170877T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028319A DE102007028319A1 (de) 2007-06-20 2007-06-20 Substituierte Oxazolidinone und ihre Verwendung
PCT/EP2008/004562 WO2008155032A1 (de) 2007-06-20 2008-06-07 Substituierte (oxazolidinon-5-yl-methyl) -2-thiophen-carboxamide und ihre verwendung im gebiet der blutgerinnung

Publications (2)

Publication Number Publication Date
DK2170877T3 true DK2170877T3 (da) 2013-02-11
DK2170877T5 DK2170877T5 (da) 2013-03-04

Family

ID=39731148

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08773372.1T DK2170877T5 (da) 2007-06-20 2008-06-07 Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering

Country Status (43)

Country Link
US (2) US8383822B2 (da)
EP (1) EP2170877B1 (da)
JP (1) JP5537421B2 (da)
KR (1) KR101535312B1 (da)
CN (1) CN101821259B (da)
AR (2) AR066981A1 (da)
AU (1) AU2008266525B8 (da)
BR (1) BRPI0813736A2 (da)
CA (1) CA2692166C (da)
CL (1) CL2008001691A1 (da)
CO (1) CO6251281A2 (da)
CR (1) CR11168A (da)
CU (1) CU23820A3 (da)
CY (1) CY1113580T1 (da)
DE (1) DE102007028319A1 (da)
DK (1) DK2170877T5 (da)
DO (1) DOP2009000285A (da)
EC (1) ECSP099807A (da)
ES (1) ES2397799T3 (da)
GT (1) GT200900319A (da)
HK (1) HK1147991A1 (da)
HN (1) HN2009003424A (da)
HR (1) HRP20130072T1 (da)
IL (1) IL202351A (da)
JO (1) JO2798B1 (da)
MA (1) MA31535B1 (da)
MX (1) MX2009013711A (da)
MY (1) MY150931A (da)
NZ (1) NZ581540A (da)
PA (1) PA8784301A1 (da)
PE (1) PE20090332A1 (da)
PL (1) PL2170877T3 (da)
PT (1) PT2170877E (da)
RS (1) RS52639B (da)
RU (1) RU2481345C2 (da)
SG (1) SG182220A1 (da)
SI (1) SI2170877T1 (da)
SV (1) SV2009003435A (da)
TN (1) TN2009000503A1 (da)
TW (1) TWI413642B (da)
UA (1) UA98793C2 (da)
UY (1) UY31133A1 (da)
WO (1) WO2008155032A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
WO2012098089A1 (en) 2011-01-19 2012-07-26 Bayer Pharma Aktiengesellschaft Binding proteins to inhibitors of coagulation factors
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
CN103232446B (zh) * 2013-05-17 2015-09-23 天津药物研究院 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途
CN104163819A (zh) * 2013-05-17 2014-11-26 天津药物研究院 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
BR9712523A (pt) 1996-10-14 2000-05-09 Bayer Ag Novos derivados de pirazol heterociclilmetil-substituìdos
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
AU6518299A (en) 1998-10-16 2000-05-08 Medical Solutions, Inc. Temperature control system and method for heating and maintaining medical items at desired temperatures
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
SK7572002A3 (en) * 1999-12-21 2002-12-03 Upjohn Co Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
AU2002354579A1 (en) * 2001-07-12 2003-01-29 Pharmacia And Upjohn Company Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound
ATE439360T1 (de) 2001-09-21 2009-08-15 Bristol Myers Squibb Co Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
KR101215153B1 (ko) 2003-11-12 2012-12-24 다이이찌 산쿄 가부시키가이샤 티아졸 유도체의 제조법
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2005179272A (ja) 2003-12-19 2005-07-07 Yamanouchi Pharmaceut Co Ltd カルボキサミド誘導体のマロン酸塩結晶
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
JP5020073B2 (ja) 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク． 第Ｘａ因子阻害剤
US20060069260A1 (en) 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
WO2006106804A1 (ja) 2005-03-31 2006-10-12 Mochida Pharmaceutical Co., Ltd. 環内窒素原子にアシル基が結合した三環系スピロ化合物
US20080221063A1 (en) 2005-07-08 2008-09-11 Astrazeneca Ab Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
RS52639B (en) 2013-06-28
RU2481345C2 (ru) 2013-05-10
PE20090332A1 (es) 2009-04-09
PL2170877T3 (pl) 2013-03-29
PT2170877E (pt) 2013-01-28
CN101821259A (zh) 2010-09-01
AR066981A1 (es) 2009-09-23
EP2170877A1 (de) 2010-04-07
HN2009003424A (es) 2012-01-05
TW200911797A (en) 2009-03-16
US20140057951A1 (en) 2014-02-27
RU2010101307A (ru) 2011-07-27
CA2692166A1 (en) 2008-12-24
NZ581540A (en) 2012-01-12
MX2009013711A (es) 2010-02-01
JP2010530383A (ja) 2010-09-09
MA31535B1 (fr) 2010-07-01
DK2170877T5 (da) 2013-03-04
MY150931A (en) 2014-03-14
US8846934B2 (en) 2014-09-30
US8383822B2 (en) 2013-02-26
BRPI0813736A2 (pt) 2014-12-30
CR11168A (es) 2010-06-28
DOP2009000285A (es) 2010-01-31
DE102007028319A1 (de) 2008-12-24
EP2170877B1 (de) 2012-11-21
CN101821259B (zh) 2013-10-30
TWI413642B (zh) 2013-11-01
SG182220A1 (en) 2012-07-30
IL202351A0 (en) 2010-06-30
AU2008266525B2 (en) 2013-09-05
CU20090216A7 (es) 2011-10-14
IL202351A (en) 2015-10-29
ECSP099807A (es) 2010-01-29
AU2008266525A1 (en) 2008-12-24
KR101535312B1 (ko) 2015-07-09
UA98793C2 (ru) 2012-06-25
CO6251281A2 (es) 2011-02-21
CU23820A3 (es) 2012-06-21
PA8784301A1 (es) 2009-02-09
CA2692166C (en) 2015-01-27
AR067057A1 (es) 2009-09-30
SV2009003435A (es) 2010-08-23
WO2008155032A1 (de) 2008-12-24
JP5537421B2 (ja) 2014-07-02
SI2170877T1 (sl) 2013-03-29
AU2008266525B8 (en) 2013-09-19
GT200900319A (es) 2011-11-09
HK1147991A1 (en) 2011-08-26
UY31133A1 (es) 2009-01-30
CL2008001691A1 (es) 2008-12-26
JO2798B1 (en) 2014-03-15
CY1113580T1 (el) 2016-06-22
US20100184740A1 (en) 2010-07-22
ES2397799T3 (es) 2013-03-11
HRP20130072T1 (hr) 2013-02-28
KR20100021615A (ko) 2010-02-25
TN2009000503A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
DK2170877T5 (da) Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering
CY2015013I2 (el) Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK2421357T3 (da) Dyremodeller og terapeutiske molekyler
BRPI0807525A2 (pt) Dispositivo endo-cirúrgico e método
DK2187980T3 (da) Hydrogel-polymersammensætninger og fremgangsmåder
NO20091424L (no) Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav
NO20091426L (no) Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav
BRPI0814330A2 (pt) métodos e kits cirúrgicos
DK2252633T3 (da) Anti-TrkA antistoffer og derivater deraf
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
BRPI0816789A2 (pt) Goji e inflamação
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK2185005T4 (da) Synergetisk sammensætning omfattende smagsstoffer og organiske syrer og anvendelse deraf
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf
DK2252688T3 (da) Syntetiske phosphodiester-oligonukleotider og terapeutiske anvendelser deraf
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
DK2293846T3 (da) Depsipeptider og deres terapeutiske anvendelse
DK2310383T3 (da) 2-oxo-alkyl-1-piperazin-2-onderivater, fremstilling deraf og terapeutisk anvendelse deraf
DK2370046T3 (da) Lægemiddeldispenser og anvendelse heraf
DK2154144T3 (da) Oligonukleotider og anvendelse deraf
BRPI0816239A2 (pt) Derivados terapêuticos de quinolina e naftaleno
DK1976853T3 (da) Nye forbindelser og anvendelse heraf
DK2099460T3 (da) 6-alkoxyalkylestradiolderivater og fremgangsmåder til anvendelse
ES1067357Y (es) Jamonero basculante y giratorio